David Dai
Stock Analyst at UBS
(4.46)
# 1,149
Out of 4,707 analysts
105
Total ratings
65%
Success rate
18.2%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Maintained: Buy | $33 | $17.28 | +90.97% | 9 | Sep 8, 2026 | |
| KURA Kura Oncology | Rated: Buy | $15 | $12.52 | +19.81% | 8 | Aug 21, 2026 | |
| SNDX Syndax Pharmaceuticals | Rated: Buy | $37 → $33 | $19.94 | +65.50% | 5 | Aug 21, 2026 | |
| CGON CG Oncology | Rated: Buy | $90 | $73.40 | +22.62% | 5 | Aug 21, 2026 | |
| IOVA Iovance Biotherapeutics | Rated: Hold | $4 → $7 | $8.70 | -19.54% | 4 | Aug 20, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | $24 → $27 | $21.69 | +24.48% | 8 | Aug 17, 2026 | |
| KYMR Kymera Therapeutics | Maintained: Buy | $128 | $116.47 | +9.90% | 3 | Aug 5, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $135 | $98.66 | +36.83% | 2 | Aug 4, 2026 | |
| NRIX Nurix Therapeutics | Rated: Buy | $23 → $31 | $26.13 | +18.64% | 6 | Jul 22, 2026 | |
| ASX: TLX Telix Pharmaceuticals Limited | Maintained: Buy | $31.00 | $16.71 | +85.57% | 14 | Jul 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $39.12 | +15.03% | 2 | Jun 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $30 | $38.19 | -21.45% | 5 | Jun 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $9 → $2 | $1.92 | +4.17% | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $69 → $15 | $20.04 | -25.15% | 2 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 | $0.7094 | +111.45% | 2 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 → $8 | $3.12 | +156.41% | 3 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $34 | $140.33 | -75.77% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $546 | $528.90 | +3.23% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $112 | $146.64 | -23.62% | 1 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 | $38.84 | +28.73% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | ¥2,690 | ¥8,810 | n/a | 6 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ¥34,600 | ¥53,550 | n/a | 1 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | ¥3,900 | ¥3,644 | n/a | 1 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $7.43 | n/a | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $5 | $4.32 | n/a | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $3.23 | n/a | 1 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 | $25.33 | n/a | 2 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $28 | $9.73 | n/a | 1 | Mar 30, 2022 |
Summit Therapeutics
Sep 8, 2026
Maintained: Buy
Price Target: $33
Current: $17.28
Upside: +90.97%
Kura Oncology
Aug 21, 2026
Rated: Buy
Price Target: $15
Current: $12.52
Upside: +19.81%
Syndax Pharmaceuticals
Aug 21, 2026
Rated: Buy
Price Target: $37 → $33
Current: $19.94
Upside: +65.50%
CG Oncology
Aug 21, 2026
Rated: Buy
Price Target: $90
Current: $73.40
Upside: +22.62%
Iovance Biotherapeutics
Aug 20, 2026
Rated: Hold
Price Target: $4 → $7
Current: $8.70
Upside: -19.54%
Cullinan Therapeutics
Aug 17, 2026
Maintained: Buy
Price Target: $24 → $27
Current: $21.69
Upside: +24.48%
Kymera Therapeutics
Aug 5, 2026
Maintained: Buy
Price Target: $128
Current: $116.47
Upside: +9.90%
BioNTech SE
Aug 4, 2026
Maintained: Buy
Price Target: $135
Current: $98.66
Upside: +36.83%
Nurix Therapeutics
Jul 22, 2026
Rated: Buy
Price Target: $23 → $31
Current: $26.13
Upside: +18.64%
Telix Pharmaceuticals Limited
Jul 1, 2026
Maintained: Buy
Price Target: $31.00
Current: $16.71
Upside: +85.57%
Jun 16, 2026
Maintained: Buy
Price Target: $45
Current: $39.12
Upside: +15.03%
Jun 4, 2026
Maintained: Hold
Price Target: $30
Current: $38.19
Upside: -21.45%
May 14, 2026
Maintained: Hold
Price Target: $9 → $2
Current: $1.92
Upside: +4.17%
Apr 15, 2026
Downgraded: Hold
Price Target: $69 → $15
Current: $20.04
Upside: -25.15%
Apr 2, 2026
Maintained: Hold
Price Target: $1.5
Current: $0.7094
Upside: +111.45%
Mar 18, 2026
Rated: Buy
Price Target: $7 → $8
Current: $3.12
Upside: +156.41%
Jan 7, 2026
Downgraded: Hold
Price Target: $40 → $34
Current: $140.33
Upside: -75.77%
Nov 7, 2025
Maintained: Buy
Price Target: $546
Current: $528.90
Upside: +3.23%
Oct 31, 2025
Reiterated: Hold
Price Target: $112
Current: $146.64
Upside: -23.62%
Oct 24, 2025
Maintained: Buy
Price Target: $50
Current: $38.84
Upside: +28.73%
Apr 2, 2025
Maintained: Hold
Price Target: ¥2,690
Current: ¥8,810
Upside: n/a
Feb 26, 2025
Reiterated: Buy
Price Target: ¥34,600
Current: ¥53,550
Upside: n/a
Jan 15, 2025
Initiated Coverage: Buy
Price Target: ¥3,900
Current: ¥3,644
Upside: n/a
Sep 29, 2022
Initiated Coverage: Buy
Price Target: $5
Current: $7.43
Upside: n/a
Jul 18, 2022
Downgraded: Hold
Price Target: $40 → $5
Current: $4.32
Upside: n/a
May 16, 2022
Maintained: Buy
Price Target: $40
Current: $3.23
Upside: n/a
May 9, 2022
Maintained: Buy
Price Target: $54
Current: $25.33
Upside: n/a
Mar 30, 2022
Initiated Coverage: Buy
Price Target: $28
Current: $9.73
Upside: n/a